Kirk Campbell, MD
Nephrology · New York, NYNPI 1184761389
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $121,897 of the $152,374 with a category attached, or 80.0%. 17 manufacturers reported payments, led by Novartis at 30.8% of the total. 2025 is the largest year on record at $62,437, more than ten times the $4,118 reported in 2019. Among nephrology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $1302.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$47K
- Travere Therapeutics, Inc.$35K
- Boehringer Ingelheim$19K
- Calliditas Therapeutics US Inc.$13K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$11K
- ANI Pharmaceuticals, Inc.$6K
- plus $22K from 11 others
Across 159 payments — averaging $6057.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$255K
- Aurinia Pharma U.S., Inc.$200K
- Astrazeneca UK Limited$159K
- Mallinckrodt Hospital Products Inc.$134K
- Vertex$91K
- Novartis$77K
- plus $47K from 1 others
What the payments were for
- Consulting fees$121,89780%
- Speaking & faculty fees$17,55012%
- Travel & lodging$8,2215%
- Food & beverage$4,7073%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $46,905 |
| Travere Therapeutics, Inc. | 38 | $35,494 |
| Boehringer Ingelheim | 11 | $18,585 |
| Calliditas Therapeutics US Inc. | 10 | $12,526 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $11,133 |
| ANI Pharmaceuticals, Inc. | 3 | $6,150 |
| Astrazeneca UK Limited | 4 | $5,349 |
| Orion Corporation | 2 | $4,250 |
| Astrazeneca AB | 4 | $3,500 |
| Sanofi US Services Inc. | 1 | $3,000 |
| Mallinckrodt Hospital Products Inc. | 1 | $1,680 |
| Sanofi | 1 | $1,274 |
| Amgen | 1 | $1,100 |
| AstraZeneca | 1 | $670 |
| Aurinia Pharma U.S., Inc. | 4 | $580 |
| Novo Nordisk | 3 | $133 |
| Salvin Dental Specialties, Inc. | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$152,374 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in New York
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
- Jai RadhakrishnanNew York$369K
- Girish NadkarniNew York$281K
- James ChevalierNew York$202K
- David CharytanNew York$164K
- Andrew BombackNew York$106K
- Alan PerlmanNew York$101K
- Phyllis AugustNew York$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.